Me-too validation study for in vitro skin irritation test with a reconstructed human epidermis model, KeraSkin™ for OECD test guideline 439.


Journal

Regulatory toxicology and pharmacology : RTP
ISSN: 1096-0295
Titre abrégé: Regul Toxicol Pharmacol
Pays: Netherlands
ID NLM: 8214983

Informations de publication

Date de publication:
Nov 2020
Historique:
received: 04 03 2020
revised: 25 06 2020
accepted: 02 07 2020
pubmed: 10 8 2020
medline: 9 7 2021
entrez: 10 8 2020
Statut: ppublish

Résumé

We conducted a me-too validation study to confirm the reproducibility, reliability, and predictive capacity of KeraSkin™ skin irritation test (SIT) as a me-too method of OECD TG 439. With 20 reference chemicals, within-laboratory reproducibility (WLR) of KeraSkin™ SIT in the decision of irritant or non-irritant was 100%, 100%, and 95% while between-laboratory reproducibility (BLR) was 100%, which met the criteria of performance standard (PS, WLR≥90%, BLR≥80%). WLR and BLR were further confirmed with intra-class correlation (ICC, coefficients >0.950). WLR and BLR in raw data (viability) were also shown with a scatter plot and Bland-Altman plot. Comparison with existing VRMs with Bland-Altman plot, ICC and kappa statistics confirmed the compatibility of KeraSkin™ SIT with OECD TG 439. The predictive capacity of KeraSkin™ SIT was estimated with 20 reference chemicals (the sensitivity of 98.9%, the specificity of 70%, and the accuracy of 84.4%) and additional 46 chemicals (for 66 chemicals [20 + 46 chemicals, the sensitivity, specificity and accuracy: 95.2%, 82.2% and 86.4%]). The receiver operating characteristic (ROC) analysis suggested a potential improvement of the predictive capacity, especially sensitivity, when changing cut-off (50% → 60-75%). Collectively, the me-too validation study demonstrated that KeraSkin™ SIT can be a new me-too method for OECD TG 439.

Identifiants

pubmed: 32768665
pii: S0273-2300(20)30151-3
doi: 10.1016/j.yrtph.2020.104725
pii:
doi:

Substances chimiques

Irritants 0

Types de publication

Journal Article Validation Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

104725

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

Juhee Han (J)

College of Pharmacy, Ewha Womans University, Seoul, Republic of Korea.

Seolyeong Kim (S)

Biosolution Co, Seoul, Republic of Korea.

Su-Hyun Lee (SH)

Biosolution Co, Seoul, Republic of Korea.

Jin-Sik Kim (JS)

COSMAX Korea, Seongnam-si, Republic of Korea.

Yu Jin Chang (YJ)

Korea Conformity Laboratories, Incheon, Republic of Korea.

Tae-Cheon Jeong (TC)

College of Pharmacy, Yeungnam University, Gyeongsan, Republic of Korea.

Mi-Jeong Kang (MJ)

College of Pharmacy, Yeungnam University, Gyeongsan, Republic of Korea.

Tae-Sung Kim (TS)

National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety, Osong, Republic of Korea.

Hae Seong Yoon (HS)

National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety, Osong, Republic of Korea.

Ga Young Lee (GY)

National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety, Osong, Republic of Korea.

SeungJin Bae (S)

College of Pharmacy, Ewha Womans University, Seoul, Republic of Korea. Electronic address: sjbae@ewha.ac.kr.

Kyung-Min Lim (KM)

College of Pharmacy, Ewha Womans University, Seoul, Republic of Korea. Electronic address: kmlim@ewha.ac.kr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH